ARA-290
Also known as: Cibinetide
Molecular Identifiers
Molecular Formula
C51H84N16O21
CAS Number
1208243-50-8
PubChem CID
91810664Molecular Weight
1257.4 Da
Overview
Synthetic 11-amino acid peptide derived from erythropoietin (EPO), designed to selectively activate the innate repair receptor (IRR) without erythropoietic effects. With a molecular weight of approximately 1,257.4 Da, it possesses neuroprotective, anti-inflammatory, and tissue repair properties without stimulating red blood cell production.
The clinical interest around ARA-290 (Cibinetide) lies in separating the reparative and anti-inflammatory effects of erythropoietin from its erythropoietic action. By selectively activating the innate repair receptor (IRR), it promotes regeneration of peripheral nerve fibers, modulates the innate immune response, and reduces pro-inflammatory cytokines without increasing hematocrit or blood viscosity. The most active research lines are painful diabetic neuropathy, sarcoidosis, and small fiber neuropathies.
ARA-290 has no regulatory approval yet; it has remained for years in investigational stages (phases 1 and 2) and continues as a research compound under development. When used outside that context, it is compounded off-label by specialized pharmacies, in daily protocols for 4 to 12 weeks. Plasma half-life is very short, but the biological effect persists via receptor internalization.
QEQLERALNSS pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser First residue is pyroglutamic acid (pGlu), not glutamine
Half-life
~2-3 minutes (IV), longer SC
Administration Route
Subcutaneous
Category
Healing & Recovery
Mechanism of Action
- Selective activation of the innate repair receptor (IRR/EPOR-βcR)
- Neuroprotection and peripheral nerve fiber repair
- Anti-inflammatory action via suppression of pro-inflammatory cytokines
- Promotion of tissue repair and cellular regeneration
- Modulation of the innate immune response
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 2-4 mg per injection |
| Frequency | Once daily |
| Timing | Morning or as directed |
| Duration | 4-12 weeks |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Headache
- Mild nausea
- Dizziness
- Injection site pain
Product Properties
| Purity | >98% |
| Appearance | White lyophilized powder |
| Solubility | Soluble in water and bacteriostatic water |
| Source | Solid-phase peptide synthesis (SPPS) |
| Storage | Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 4 weeks. Protect from light and moisture. Avoid repeated freeze-thaw cycles. |
Presentations & Preparation
Vials of ARA-290 found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per vial
- Inject the diluent slowly against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on ARA-290.
ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes
Brines M, Dunne AN, van Velzen M, Proto PL, Ostenson CG, Kirk RI, Petropoulos IN, Javed S, Malik RA, Cerami A, Dahan A
Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study
Heij L, Niesters M, Swartjes M, Hoitsma E, Drent M, Dunne A, Grutters JC, Vogels O, Brines M, Cerami A, Dahan A
Related Peptides
BPC-157
250-500 mcg per injection · 1-2 times daily
Cartalax
1-2 capsules orally (0.2 g per capsule, containing AKS-4 peptide complex) · 1-2 times daily, with meals
GHK-Cu
1-3 mg per injection · Once daily or every other day
LL-37
50-200 mcg per injection · Once daily
MGF
200-400 mcg per injection · Once daily (MGF) or 2-3 times per week (PEG-MGF)
TB-500
2-5 mg per injection · Twice per week